BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†6
*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)
†BRILIQUE (ticagrelor) 90mg b.d. in combination with ASA is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg b.d. is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment
Mode of Action
BRILIQUE inhibits the P2Y12 receptor10,6
BRILIQUE binds to a site on the P2Y12 receptor that is distinct from both the ADP and thienopyridine binding sites. BRILIQUE ‘locks’ the receptor in an inactive state, preventing the conformational changes that are needed to allow signal transduction.
Thienopyridines, such as clopidogrel and prasugrel, bind to the same site on the P2Y12 receptor as adenosine diphosphate (ADP). However, they bind irreversibly to the P2Y12 receptor, rendering it nonfunctional for the life of the platelet.10,7